This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03520686
Recruitment Status : Active, not recruiting
First Posted : May 11, 2018
Last Update Posted : February 7, 2024
Sponsor:
Information provided by (Responsible Party):
ImmunityBio, Inc.

Tracking Information
First Submitted Date  ICMJE April 19, 2018
First Posted Date  ICMJE May 11, 2018
Last Update Posted Date February 7, 2024
Actual Study Start Date  ICMJE May 18, 2018
Estimated Primary Completion Date October 1, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 27, 2018)
Progression Free Survival (PFS) [ Time Frame: 24 Months ]
Defined by RECIST Version 1.1 based on BICR
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 29, 2020)
  • Overall Survival (OS) [ Time Frame: 24 Months ]
  • Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR
  • Duration of Response (DOR) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR.
  • PFS [ Time Frame: 24 Months ]
    Defined by iRECIST based on BICR.
  • Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined by iRECIST based on BICR.
  • Duration of Response (DOR) [ Time Frame: 24 Months ]
    Defined by iRECIST based on BICR.
  • Disease Control Rate (DCR) [ Time Frame: 2 Months ]
    Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR
  • Quality of Life based on Patient Reported Outcomes Questionnaires [ Time Frame: 24 Months ]
    FACT-L
Original Secondary Outcome Measures  ICMJE
 (submitted: April 27, 2018)
  • Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR
  • Overall Survival (OS) [ Time Frame: 24 Months ]
  • Duration of Response (DOR) [ Time Frame: 24 Months ]
    Defined by RECIST Version 1.1 based on BICR.
  • Disease-specific survival (DSS) [ Time Frame: 24 Months ]
  • Disease Control Rate (DCR) [ Time Frame: 2 Months ]
    Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR
  • PFS [ Time Frame: 24 Months ]
    Defined by irRC based on BICR.
  • Overall Response Rate (ORR) [ Time Frame: 24 Months ]
    Defined by irRC based on BICR.
  • Duration of Response (DOR) [ Time Frame: 24 Months ]
    Defined by irRC based on BICR.
Current Other Pre-specified Outcome Measures
 (submitted: July 29, 2020)
  • Incidence of treatment-emergent AEs and SAEs [ Time Frame: 24 Months ]
    Graded using the NCI CTCAE Version 5.0
  • Immunogenicity profile of N-803 in combination with pembrolizumab. [ Time Frame: 24 Months ]
    Detection of anti-drug antibodies
  • Tumor molecular profiles and correlations with subject outcomes [ Time Frame: 9 Weeks ]
    Genomic sequencing of tumor cells from tissue
Original Other Pre-specified Outcome Measures
 (submitted: April 27, 2018)
  • Incidence of treatment-emergent AEs and SAEs [ Time Frame: 24 Months ]
    Graded using the NCI CTCAE Version 4.03
  • Serum concentration of ALT-803 [ Time Frame: 24 Months ]
    maximum observed concentration (Cmax)
  • Immunogenicity profile of ALT-803 in combination with pembrolizumab. [ Time Frame: 24 Months ]
    Detection of anti-drug antibodies
  • Tumor molecular profiles and correlations with subject outcomes [ Time Frame: 9 Weeks ]
    Genomic sequencing of tumor cells from tissue
  • Molecular changes in ctDNA and ctRNA and correlations with subject outcomes. [ Time Frame: 24 Months ]
    Expression levels of specific tumor- and immune-related analytes in ctDNA and ctRNA will be measured by qPCR
 
Descriptive Information
Brief Title  ICMJE QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.
Official Title  ICMJE QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Brief Summary This is a phase 3, open-label, 3-cohort, randomized study to compare the safety and efficacy of N-803 in combination with the current standard of care (experimental arms) versus standard of care alone (control arms), as first-line treatment for subjects with stage 3 or 4 advanced or metastatic NSCLC. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: N-803 + Pembrolizumab

    The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

    Day 1, every 3 weeks:

    • Pembrolizumab (200 mg intravenous infusion [IV])
    • N-803 (15 μg/kg subcutaneously [SC])
  • Drug: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab

    The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

    Induction (4 cycles):

    Day 1, every 3 weeks:

    • Carboplatin (up to 900mg IV)
    • Nab-paclitaxel (100mg/m² IV)
    • Pembrolizumab (200mg IV)
    • N-803 (15 μg/kg SC)

    Day 8:

    • Nab-paclitaxel (100mg/m² IV)

    Day 15:

    • Nab-paclitaxel (100mg/m² IV)

    Maintenance:

    Day 1, every 3 weeks:

    • Pembrolizumab (200mg IV)
    • N-803 (15 μg/kg SC)
  • Drug: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed

    The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

    Induction (4 cycles):

    Day 1, every 3 weeks:

    • Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)
    • Pembrolizumab (200mg IV)
    • Pemetrexed (500mg/m² IV)
    • N-803 (15 μg/kg SC)

    Maintenance:

    Day 1, every 3 weeks:

    • Pembrolizumab (200mg IV)
    • N-803 (15 μg/kg SC)
  • Drug: Pembrolizumab

    Drug: Pembrolizumab

    The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

    Day 1, every 3 weeks:

    • Pembrolizumab (200 mg IV)

  • Drug: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab

    The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

    Induction (4 cycles):

    Day 1, every 3 weeks:

    • Carboplatin (up to 900mg IV)
    • Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)
    • Pembrolizumab (200mg IV)

    Day 8:

    • Nab-paclitaxel (100mg/m² IV) -if assigned to receive

    Day 15:

    • Nab-paclitaxel (100mg/m² IV) -if assigned to receive

    Maintenance:

    Day 1, every 3 weeks:

    • Pembrolizumab (200mg IV)
  • Drug: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed

    The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:

    Induction (4 cycles):

    Day 1, every 3 weeks:

    • Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)
    • Pembrolizumab (200mg IV)
    • Pemetrexed (500mg/m² IV)

    Maintenance:

    Day 1, every 3 weeks:

    • Pembrolizumab (200mg IV)
Study Arms  ICMJE
  • Experimental: Cohort A (Experimental)
    Intervention: Drug: N-803 + Pembrolizumab
  • Experimental: Cohort B (Experimental)
    Intervention: Drug: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab
  • Experimental: Cohort C (Experimental)
    Intervention: Drug: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
  • Active Comparator: Cohort A (Control)
    Intervention: Drug: Pembrolizumab
  • Active Comparator: Cohort B (Control)
    Intervention: Drug: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab
  • Active Comparator: Cohort C (Control)
    Intervention: Drug: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: July 29, 2020)
1538
Original Estimated Enrollment  ICMJE
 (submitted: April 27, 2018)
388
Estimated Study Completion Date  ICMJE April 1, 2026
Estimated Primary Completion Date October 1, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age ≥ 18 years old.
  2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
  3. Histologically-confirmed stage 3 or 4 NSCLC disease. Subjects with stage 3 disease must not be candidates for treatment with surgical resection or chemoradiation.
  4. Subjects must not have received prior systemic chemotherapy for advanced or metastatic NSCLC. Previous neoadjuvant/adjuvant chemotherapy is allowed if completed ≥ 6 months before diagnosis of metastatic disease. Subject's with newly-diagnosed stage 4 NSCLC may have previously received systemic chemotherapy for stage 3 NSCLC.
  5. For Cohort A only: NSCLC tumors must have PD-L1 expression (i.e. a TPS ≥1%) as determined by an FDA-approved test.
  6. The subject's tumor must not harbor an EGFR sensitizing (activating) mutation or ALK translocation or targetable genomic aberration in BRAF, ROS1 or NTRK. EGFR sensitizing mutations are those mutations that are amenable to treatment with tyrosine kinase inhibitors including erlotinib, gefitinib, or afatinib. Investigators must be able to produce the source documentation of the EGFR mutation, ALK translocation, and BRAF, ROS1, and NTRK status. If any of the genomic changes described above are detected, additional information regarding the mutation status of other molecules is not required. If unable to test for these molecular changes, formalin fixed paraffin embedded tumor tissue of any age should be submitted to a central laboratory designated by the Sponsor for such testing. Subjects will not be randomized until the EGFR , BRAFT, ROS1, and NTRK mutation status and ALK translocation status is available in source documentation at the site.
  7. ECOG performance status of 0 or 1.
  8. Measurable tumor lesions according to RECIST 1.1.
  9. Must be willing to release tumor biopsy specimen used for diagnosis of advanced or metastatic NSCLC (if available) for exploratory tumor molecular profiling. If tumor biopsy specimen is not available, subjects can still be enrolled.
  10. Must be willing to provide blood samples prior to the start of treatment on this study for exploratory tumor molecular profiling analysis.
  11. Must be willing to provide a tumor biopsy specimen 9 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  12. Ability to attend required study visits and return for adequate follow-up, as required by this protocol
  13. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), hormonal therapy, and abstinence.

Exclusion Criteria:

  1. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
  2. A history of prior malignancy with the following exceptions: cancer treated with curative therapy with no disease recurrence for >3 years, non-metastatic prostate cancer controlled with hormonal therapy, or under observation; non-metastatic thyroid cancer; basal or squamous cell carcinoma of the skin, superficial bladder cancer, or in situ cervical cancer that has undergone successful definitive resection.
  3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma).
  4. History of organ transplant requiring immunosuppression; or history of pneumonitis or interstitial lung disease requiring treatment with systemic steroids; or a history of receiving systemic steroid therapy or any other immunosuppressive medication ≤ 3 days prior to study initiation. Daily steroid replacement therapy (eg, prednisone or hydrocortisone) and corticosteroid use to manage AEs are permitted.
  5. Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of study initiation.
  6. Requirement for other forms of anticancer treatment while on trial, including maintenance therapy, other radiation therapy, and/or surgery. Palliative radiation is permitted.
  7. Known CNS metastases or carcinomatous meningitis. Subjects with previously treated, stable CNS metastases (no evidence of progression for ≥ 4 weeks, and resolution of neurologic symptoms to baseline state) are permitted in this study.
  8. History of receiving a live vaccine 30 days prior to study treatment.
  9. History of human immunodeficiency virus (HIV), or known active hepatitis B or C infection.
  10. An active infection requiring systemic IV therapy.
  11. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  12. Inadequate organ function, evidenced by the following laboratory results:

    1. Absolute neutrophil count < 1,500 cells/mm3.
    2. Platelet count < 100,000 cells/mm3.
    3. Total bilirubin greater the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
    4. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 1.5 × ULN.
    5. Alkaline phosphatase (ALP) levels > 2.5 × ULN.
    6. Serum creatinine > 2.0 mg/dL or 177 μmol/L or creatinine clearance < 40 mL/min (using the Cockcroft-Gault formula)
  13. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
  14. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
  15. Known hypersensitivity to any component of the study medication(s).
  16. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  17. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
  18. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  19. Concurrent participation in any interventional clinical trial.
  20. Pregnant and nursing women.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03520686
Other Study ID Numbers  ICMJE QUILT-2.023
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party ImmunityBio, Inc.
Original Responsible Party Altor BioScience
Current Study Sponsor  ICMJE ImmunityBio, Inc.
Original Study Sponsor  ICMJE Altor BioScience
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Deborah Fridman VP, Clinical Operations & Development
PRS Account ImmunityBio, Inc.
Verification Date August 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP